Dr. Reddy's, Gilead Enter Remdesivir Licensing Agreement

Marco Green
June 29, 2020

In a release, the Ministry of Health and Family Welfare intimated the updated Clinical Management Protocol for COVID-19, in which the drug Remdesivir has been included as an "investigational therapy" only for restricted emergency use purposes along with off label use of Tocilizumab and Convalescent Plasma. "At this critical juncture, we join hands once again to ensure that no efforts are spared in the fight against this pandemic".

As part of the agreementsthey have signed, the drugmakers receive technology transfer of the manufacturing process for remdesivir and get to set their own prices for the generic product they produce, Gilead said.

"Under the agreement, the licence is royalty free until another pharmaceutical product or vaccine is approved for the treatment or prevention of COVID-19 by the USFDA or EMA (European Medicines Agency) or the WHO (World Health Organization) announcing the end of the public health emergency", it added.

Remdesivir is an investigational nucleotide analog with broad-spectrum antiviral activity both in vitro and in vivo in animal models against multiple emerging viral pathogens, including Ebola, Marburg, MERS and SARS.

Sources said the state's Covid-19 task force that comprises doctors who look into clinical management and reports to Chief Minister Uddhav Thackeray suggested the use of remdesivir to save lives.

Restricted Emergency Use of drugs in the country for treatment of suspected or laboratory confirmed COVID-19 in adults and children hospitalised with severe disease is subject to the following conditions- Written informed consent of each patient required, results of additional clinical trials to be submitted, active surveillance data of all treated patients to be submitted, risk management plan along with active post marketing surveillance and reporting of serious adverse events also to be submitted.

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.374 as compared to the previous close of Rs. 369.6. "ICMR's testing capacity for detecting coronavirus in infected persons is continuously being ramped up and the number of government labs has been increased to 646 and private labs to 247, taking the total to 893".

The stock hit an intraday high of Rs. 376.5 and intraday low of 360.35.

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER